Please login to the form below

Not currently logged in
Email:
Password:

Bayer promotes Robert LaCaze

He becomes EVP of new oncology strategic business unit

Leverkusen, Germany-based Bayer has promoted Robert LaCaze to executive vice president of its new oncology strategic business unit, part of the firm's pharmaceutical division.

LaCaze joins the pharmaceutical division's executive committee, and will be responsible for implementing the new unit's accelerated development model for new oncology therapies.

He first joined Bayer in 2015 and most recently served as senior vice president and head of global oncology therapeutic area at the firm.

Prior to this, LaCaze spent 27 years at Bristol-Myers Squibb, holding a series of increasingly senior oncology-focused managerial roles, before becoming senior vice president and head of product and portfolio strategy at Bristol-Myers Squibb in 2014.

Dieter Weinand, head of the Bayer Pharmaceutical executive committee, said: “We are delighted to have an executive with Robert LaCaze's experience and talent lead the Oncology Strategic Business Unit.

“I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”

9th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics